ReviewNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2025
Converging pathologies in neurodegeneration: the mechanistic interplay between α-Synuclein and Tau in Alzheimer's and Parkinson's.
Review in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Co- and multipathologies need serious consideration for understanding Parkinson's disease pathogenesis and designing novel experimental therapeutic strategies.Journal of Parkinson's disease · 2026Article
- Co- and Multi-Pathologies in Parkinson's Disease: An International Parkinson and Movement Disorder Society Scientific Issues Committee Review.Movement disorders : official journal of the Movement Disorder Society · 2026Review
- Review
- Amyloid-β, Tau Protein, α-Synuclein, TDP-43, and FUS in Mixed Pathology: And Intrinsic Disorder to Rule Them All.International journal of molecular sciences · 2026Review
- Alpha-Synuclein in Neurodegeneration: From Shared Biology to Disease-Specific Phenotypes.Cells · 2026Review
- Toward common treatment strategies: convergent proteinopathies and mitochondrial dysfunction in Alzheimer's and Parkinson's diseases.Frontiers in neuroscience · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Alzheimer's and Parkinson's disease are the most prevalent neurodegenerative disorders globally, each characterized by distinct pathological hallmarks; primarily tau neurofibrillary tangles and amyloid-beta plaques in AD, and alpha-synuclein (α-Syn) Lewy bodies in PD. However, evidence suggests a complex interplay between these proteins, particularly α-Syn and tau, which may contribute to the progression of both diseases. Recent observations demonstrate the co-occurrence of α-Syn and tau pathologies in both AD and PD patients. At the molecular level, both proteins exhibit prion-like propagation properties and can undergo cross-seeding, where one misfolded protein species induces the misfolding, aggregation of the other and increasing neurotoxicity. These proteins also share common post-translational modifications, cellular clearance mechanisms, and are influenced by similar microenvironmental factors that favor protein aggregation. This review explores the potential mechanisms by which α-Syn in PD may influence tau pathology, potentially exacerbating AD like disease progression that may potentially contribute to cognitive decline in PD. This review also delves into the underlying molecular pathways, such as prion-like propagation, cross-seeding, and inflammatory responses that could mediate this interaction, leading to enhanced neurodegeneration in comorbid cases. Further, various clinical implications of proteins' interplay, relevance to mixed neurodegenerative phenotypes, and potential therapeutic strategies targeting both α-Syn and tau pathologies have also been discussed in this manuscript.
Indexed as
Identifiers
40856744What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.